Here, we investigated the expression levels and therapeutic potential of DNA2 depletion in pancreatic cancers, where 90–95% cases are associated with an activating mutation in the K-Ras oncogene.35, 36, 37 Analysis of gene expression patterns in pancreatic cancers in the Oncomine database shows that DNA2 is significantly upregulated.33 Consistently, an elevated DNA2 protein level was observed in pancreatic cancer patient specimens (Figure 1a). This evidence concerns the gene KRAS and familial pancreatic carcinoma.